{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:15:28Z","timestamp":1793650528040,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01062-x","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:59:11Z","timestamp":1784685551000},"page":"1057-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updated Integrated Safety Analysis of Ritlecitinib up to ~\u00a05\u00a0Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct03732807","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04006457","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04517864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02974868","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Maryanne","family":"Senna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Aguh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Sadrarhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"2","key":"1062_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1062_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"1062_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1062_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.14959","volume":"32","author":"M-A Richard","year":"2018","unstructured":"Richard M-A, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the \u00ab\u202fOBJECTIFS PEAU\u202f\u00bb study. J Eur Acad Dermatol Venereol. 2018;32(11):1967\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1062_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257\u201365.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1062_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"1062_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556-8.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1062_CR8","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"6","key":"1062_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s13555-025-01417-y","volume":"15","author":"KA Hanson","year":"2025","unstructured":"Hanson KA, Va\u00f1\u00f3-Galv\u00e1n S, Messenger A, et al. Comparison of Dermatology Life Quality Index scores in adults and adolescents with alopecia areata. Dermatol Ther. 2025;15(6):1543\u201353.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1062_CR10","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1007\/s12325-025-03302-8","volume":"42","author":"KA Hanson","year":"2025","unstructured":"Hanson KA, Austin J, Clayton N, et al. Patient-reported psychosocial burdens and quality of life and work productivity impacts among patients with clinically distinct alopecia areata severity profiles. Adv Ther. 2025;42(9):4556\u201370.","journal-title":"Adv Ther"},{"key":"1062_CR11","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s13555-024-01280-3","volume":"14","author":"P Anderson","year":"2024","unstructured":"Anderson P, Piercy J, Austin J, et al. Alopecia areata treatment patterns and satisfaction: results of a real-world cross-sectional survey in Europe. Dermatol Ther. 2024;14:3243\u201358.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1062_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"1062_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nm.3685","volume":"20","author":"SJ Divito","year":"2014","unstructured":"Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. Nat Med. 2014;20(9):989\u201390.","journal-title":"Nat Med"},{"issue":"6","key":"1062_CR14","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235\u201342.","journal-title":"ACS Chem Biol"},{"issue":"4","key":"1062_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","volume":"149","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318\u201328.","journal-title":"J Allergy Clin Immunol"},{"issue":"10387","key":"1062_CR16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"2","key":"1062_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1062_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"M Piliang","year":"2025","unstructured":"Piliang M, Soung J, King B, et al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u00a0months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215\u201327.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1062_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299\u2013314.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1062_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13555-023-00937-9","volume":"13","author":"P George","year":"2023","unstructured":"George P, Jagun O, Liu Q, et al. Incidence rates of infections, malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US claims database. Dermatol Ther. 2023;13(8):1733\u201346.","journal-title":"Dermatol Ther"},{"key":"1062_CR21","doi-asserted-by":"publisher","first-page":"adv42646","DOI":"10.2340\/actadv.v105.42646","volume":"105","author":"SBT S\u00f8rensen","year":"2025","unstructured":"S\u00f8rensen SBT, George P, Jagun O, et al. Rates of infections, malignancies, cardiovascular outcomes, and death in individuals with hospital-treated alopecia areata: a registry-based cohort study in Denmark. Acta Derm Venereol. 2025;105:adv42646.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1062_CR22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ced\/llac106","volume":"48","author":"AG Messenger","year":"2023","unstructured":"Messenger AG, Harries M, Macbeth AE, et al. Alopecia areata and risk of common infections: a population-based cohort study. Clin Exp Dermatol. 2023;48(4):332\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1062_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/1346-8138.17643","volume":"52","author":"Y Ma","year":"2025","unstructured":"Ma Y, Chachin M, Hirose T, et al. Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database. J Dermatol. 2025;52(5):841\u201354.","journal-title":"J Dermatol"},{"key":"1062_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00403-025-04258-z","volume":"317","author":"J Levine","year":"2025","unstructured":"Levine J, Islam RK, Mo L, et al. Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study. Arch Dermatol Res. 2025;317:757.","journal-title":"Arch Dermatol Res"},{"key":"1062_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03306-4","volume":"316","author":"PY Ch\u2019en","year":"2024","unstructured":"Ch\u2019en PY, Konisky H, Kobets K. Alopecia areata does not increase the risk of venous thromboembolism: an All of Us case-control study. Arch Dermatol Res. 2024;316:574.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1062_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamadermatol.2023.5509","volume":"160","author":"PA Ireland","year":"2024","unstructured":"Ireland PA, Jansson N, Spencer SKR, Braden J, Sebaratnam D. Short-term cardiovascular complications in dermatology patients receiving JAK-STAT inhibitors: a meta-analysis of randomized clinical trials. JAMA Dermatol. 2024;160(3):281\u20139.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1062_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"JP Ingrassia","year":"2024","unstructured":"Ingrassia JP, Maqsood MH, Gelfand JM, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(1):28\u201336.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1062_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1204","volume":"12","author":"S Anderson","year":"2024","unstructured":"Anderson S, Cavaletti G, Hood LJ, et al. A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata. Pharmacol Res Perspect. 2024;12(4):e1204.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"1062_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40257-025-00932-0","volume":"26","author":"B King","year":"2025","unstructured":"King B, Mostaghimi A, Shimomura Y, et al. Safety of baricitinib in adults with severe alopecia areata from two phase III trials over a median of 2.3\u00a0years and up to 4\u00a0years of treatment. Am J Clin Dermatol. 2025;26(4):611\u201322.","journal-title":"Am J Clin Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01062-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:31:51Z","timestamp":1789464711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01062-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maryanne Senna is a member on a scientific advisory board and\/or consultant for Eli Lilly, BiologicsMD, Pfizer Inc, Arena Pharmaceuticals, Inmagene, Kintor, and L\u2019Or\u00e9al; is a speaker for Eli Lilly and Pfizer Inc; received research funding from Eli Lilly, Concert, Clarity, Follica, LEO Pharma, and Santiste; is a member on the board of directors for the Scarring Alopecia Foundation and American Hair Research Society; and co-director of the CorEvitas AA Registry. Sameh Hanna is a clinical trialist for AbbVie, Lilly, Lumenis, and Pfizer Inc and received honoraria for speaking\/consulting from AbbVie, Lilly, and Pfizer Inc. Rie Ueki is a clinical trial investigator for Pfizer Inc. Xingqi Zhang has no conflict of interest. Crystal Aguh serves as a consultant for Pfizer, Lilly, and Myovant Sciences. She is on the advisory board for Olaplex, Veradermics, and CPSkin Health. She is the editor of the UpToDate section on Central Centrifugal Cicatricial Alopecia, for which she receives royalties. Her research program is supported through an educational grant by Lilly. Bianca Maria Piraccini received honoraria for participation in advisory boards, being a speaker, and\/or being a consultant for Almirall, Pfizer Inc, Eli Lilly, Pierre Fabre-Ducray, Cantabria-Difa Cooper, Dercos-L\u2019Oreal, ISDIN, and Legacy Healthcare. Edward Nagy, Mojgan Sadrarhami, Simon Chen, Robert Wolk, Alexandre Lejeune, and Helen Tran are employees of and hold stock or stock options in Pfizer.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained for individual studies included in the analysis. The study was performed in accordance with the ethical standards as provided in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants of the individual studies included in this analysis.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients signed informed consent regarding publishing their data.","order":4,"name":"Ethics","label":"Patient Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See\n                      \n                      for more information.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the concept and design of the study, to data analysis and interpretation, to critical revision of the publication, and all authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}